Citadel Advisors’s Dyne Therapeutics DYN Stock Holding History

Citadel Advisors’s Portfolio DYN Stock Details DYN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$464K	Buy	25,600 +6,400	+33%	+$110K	﹤0.01%	9488
2025 Q4	$376K	Buy	19,200 +5,300	+38%	+$100K	﹤0.01%	9671
2025 Q3	$176K	Buy	+13,900	New	+$159K	﹤0.01%	11394
2025 Q2	–	Sell	-28,600	Closed	-$299K	–	13097
2025 Q1	$299K	Buy	28,600 +19,400	+211%	+$278K	﹤0.01%	9606
2024 Q4	$217K	Sell	9,200 -4,100	-31%	-$121K	﹤0.01%	10301
2024 Q3	$478K	Buy	13,300 +7,500	+129%	+$298K	﹤0.01%	8354
2024 Q2	$205K	Sell	5,800 -29,200	-83%	-$849K	﹤0.01%	9882
2024 Q1	$994K	Buy	35,000 +11,500	+49%	+$260K	﹤0.01%	6926
2023 Q4	$313K	Buy	23,500 +17,700	+305%	+$173K	﹤0.01%	9085
2023 Q3	$52K	Buy	5,800 +1,900	+49%	+$20.5K	﹤0.01%	11716
2023 Q2	$43.9K	Buy	3,900 +3,500	+875%	+$41.3K	﹤0.01%	11963
2023 Q1	$4.61K	Sell	400 -3,800	-90%	-$49.4K	﹤0.01%	13938
2022 Q4	$48.7K	Buy	+4,200	New	+$48.6K	﹤0.01%	12177

Other funds holding DYN

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

AVLSA

Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

OAG

Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

FIS

FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return

Citadel Advisors's DYN Position: Q1 2026 in Review

Citadel Advisors reduced its Dyne Therapeutics (DYN) stake by 83% in Q1 2026, selling an estimated $16.7M and leaving 201,144 shares worth $3.65M. The position accounts for ﹤0.01% of the portfolio, ranked #4884.

Citadel Advisors first reported a position in DYN in Q3 2020 and has held it in 23 quarters since. The position peaked at $152M in Q2 2024. 227 funds tracked by Wall St. Rank hold DYN as of Q1 2026.

Citadel Advisors held 201,144 shares of Dyne Therapeutics worth $3.65M as of Q1 2026.
Citadel Advisors sold 970,480 Dyne Therapeutics shares in Q1 2026, an estimated $16.7M.
Dyne Therapeutics made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #4884 holding.
Citadel Advisors first reported a position in Dyne Therapeutics in Q3 2020 and has held it in 23 quarters since.
Citadel Advisors's Dyne Therapeutics position peaked at $152M in Q2 2024.
227 funds tracked by Wall St. Rank held Dyne Therapeutics as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.